spacer
home > ebr > > proteolytic enzymes as therapeutic targets
PUBLICATIONS
European Biopharmaceutical Review

Proteolytic Enzymes as Therapeutic Targets

The regulation of protein secretion is central to the proper functioning of eukaryotic organisms. One mode of protein secretion is the generation of soluble fragments of membrane-bound proteins by limited proteolysis through the action of proteases termed secretases, or sheddases. In general, cleavage occurs close to the extracellular face of the membrane, releasing active protein. Proteins secreted in this fashion include some membrane receptors and receptor ligands, ectoenzymes and cell adhesion molecules. Since the proteins concerned are involved in pathophysiological processes, such as neurodegeneration, inflammation and oncogenesis, inhibitors of respective secretases are emerging as promising therapeutic drugs. This article will review a number of methods that have allowed molecular cloning of secretases and discuss different approaches to discovering specific secretase inhibitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Urs Lüthi, Senior Scientist at ESBATech

Dr Urs Lüthi carried out his PhD studies at ESBATech under the supervision of Dr Alcide Barberis and has recently completed his dissertation on the subject of functional screening systems in yeast to identify secretases, targets of secretases and modulators of secretase activity. An essential part of his work focused on the development of the cellular assay for BACE activity that is further developed for small compound inhibitors screens.
He will continue to develop his expertise as a Senior Scientist with ESBATech and will be responsible for the development of similar cell-based assay systems. Urs' academic work was presented at several international conferences and published in peer-reviewed journals.

spacer
Dr Urs Lüthi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Veeva Systems Introduces Veeva OpenKey - Veeva Unveils a New Approach to Customer Reference Data that’s Open, Easy, and Global

BARCELONA, SPAIN – 24 March, 2015 – On opening day of eyeforpharma Barcelona 2015, Veeva Systems (NYSE: VEEV) announced Veeva OpenKey, a new approach to customer reference data for the life sciences industry. Veeva OpenKey builds on Veeva’s growing presence in the data business with a bold vision to provide customer data for all healthcare professionals (HCP), healthcare organisations (HCO), and affiliations across life sciences’ major markets—and to do so with consistent standards for quality and service.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Exploratory Clinical Development World Europe

2-3 June 2015, Bishopsgate, London, UK

Exploratory Clinical Development World Europe is recognised as the premier conference for understanding the right strategies and methods to assess safety & efficacy and make timely go/no go decisions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement